5:54 PM
 | 
Dec 05, 2013
 |  BC Extra  |  Company News

G-BA says 'no additional benefit' for Stribild

Germany's Federal Joint Committee (G-BA) said in a final benefit assessment that HIV drug Stribild from Gilead Sciences Inc. (NASDAQ:GILD) has "no additional benefit" over Atripla emtricitabine/tenofovir/efavirenz, a comparator requested by G-BA, in therapy-naïve patients. In a September preliminary assessment,...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >